MX377634B - Anticuerpos humanos contra fel d1 y métodos de uso de los mismos. - Google Patents

Anticuerpos humanos contra fel d1 y métodos de uso de los mismos.

Info

Publication number
MX377634B
MX377634B MX2014013371A MX2014013371A MX377634B MX 377634 B MX377634 B MX 377634B MX 2014013371 A MX2014013371 A MX 2014013371A MX 2014013371 A MX2014013371 A MX 2014013371A MX 377634 B MX377634 B MX 377634B
Authority
MX
Mexico
Prior art keywords
antibodies
fel
allergen
methods
basophils
Prior art date
Application number
MX2014013371A
Other languages
English (en)
Other versions
MX2014013371A (es
Inventor
Andrew J Murphy
Jamie Orengo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX377634(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2014013371A publication Critical patent/MX2014013371A/es
Publication of MX377634B publication Critical patent/MX377634B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención proporciona anticuerpos que unen al alergénico de gato, Fel d1, composiciones que comprenden los anticuerpos, ácidos nucleicos que codifican a los anticuerpos y los métodos de uso de los anticuerpos. De acuerdo con ciertas modalidades de la invención, los anticuerpos son los anticuerpos monoclonales completamente humanos que unen a Fel d1. Los anticuerpos de la invención son útiles para unir al alergénico Fel d1 in vivo previniendo así la unión del alergénico Fel d1 a IgE preformado en la superficie de los mastocitos o de los basofilos. Al hacer esto, los anticuerpos actúan para prevenir la liberación de histamina y otros mediadores inflamatorios de los mastocitos y/o de los basófilos, mejorando así la respuesta inconveniente al alergénico de gato en individuos sensibilizados. Los anticuerpos de la invención también pueden ser útiles para que los propósitos del diagnóstico determinen si un paciente es alérgico al alergénico de gato Fel d1.
MX2014013371A 2012-05-03 2013-05-02 Anticuerpos humanos contra fel d1 y métodos de uso de los mismos. MX377634B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261642083P 2012-05-03 2012-05-03
US201261718044P 2012-10-24 2012-10-24
US201361783312P 2013-03-14 2013-03-14
PCT/US2013/039192 WO2013166236A1 (en) 2012-05-03 2013-05-02 Human antibodies to fel d1 and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2014013371A MX2014013371A (es) 2015-02-05
MX377634B true MX377634B (es) 2025-03-10

Family

ID=48326501

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013371A MX377634B (es) 2012-05-03 2013-05-02 Anticuerpos humanos contra fel d1 y métodos de uso de los mismos.
MX2020003864A MX2020003864A (es) 2012-05-03 2014-11-03 Anticuerpos humanos contra fel d1 y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003864A MX2020003864A (es) 2012-05-03 2014-11-03 Anticuerpos humanos contra fel d1 y metodos de uso de los mismos.

Country Status (33)

Country Link
US (6) US9079948B2 (es)
EP (4) EP3660047B1 (es)
JP (2) JP6400569B2 (es)
KR (1) KR102185516B1 (es)
CN (2) CN104411719B (es)
AR (1) AR090914A1 (es)
AU (2) AU2013256251C1 (es)
BR (2) BR122019023685B1 (es)
CA (1) CA2871077C (es)
CY (2) CY1124023T1 (es)
DK (2) DK2844672T3 (es)
ES (3) ES2780392T3 (es)
FI (1) FI3978522T3 (es)
HR (2) HRP20200652T1 (es)
HU (2) HUE057062T2 (es)
IL (1) IL235121B (es)
IN (1) IN2014DN08767A (es)
JO (1) JO3820B1 (es)
LT (3) LT3978522T (es)
MX (2) MX377634B (es)
MY (3) MY195564A (es)
NZ (2) NZ701124A (es)
PL (2) PL3660047T3 (es)
PT (3) PT2844672T (es)
RS (2) RS62636B1 (es)
RU (1) RU2658491C2 (es)
SG (3) SG10201608378UA (es)
SI (3) SI3978522T1 (es)
SM (3) SMT202500396T1 (es)
TW (2) TW201803901A (es)
UY (1) UY34782A (es)
WO (1) WO2013166236A1 (es)
ZA (3) ZA201407302B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PT3221359T (pt) 2014-11-17 2020-06-23 Regeneron Pharma Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
JP6773679B2 (ja) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
WO2017042241A1 (en) * 2015-09-08 2017-03-16 Universität Zürich Compositions against cat allergy
MX393066B (es) 2016-04-18 2025-03-24 Celldex Therapeutics Inc Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
WO2018118713A1 (en) * 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
US10774137B2 (en) 2017-01-24 2020-09-15 Société des Produits Nestlé S.A. Compositions and methods for reducing at least one symptom of human allergy to cats
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
SG11202004380QA (en) 2017-12-22 2020-06-29 Regeneron Pharma System and method for characterizing drug product impurities
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
BR112020013426A2 (pt) 2018-02-28 2020-12-01 Regeneron Pharmaceuticals, Inc. métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EA202092203A1 (ru) 2018-03-19 2020-12-07 Ридженерон Фармасьютикалз, Инк. Способы анализа и реагенты для микрочипового капиллярного электрофореза
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN112166119B (zh) * 2018-05-18 2024-12-20 陈扎克伯格生物中心旧金山公司 从人中分离过敏原特异性抗体的方法及其用途
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
TWI866924B (zh) 2018-08-30 2024-12-21 美商再生元醫藥公司 用於將蛋白質複合物定特徵之方法
CN117110492A (zh) 2019-01-16 2023-11-24 瑞泽恩制药公司 鉴别蛋白质中的游离巯基的方法
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
BR112022004885A2 (pt) 2019-09-24 2022-06-07 Regeneron Pharma Sistemas e métodos para uso e regeneração de cromatografia
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
IL293112A (en) 2019-11-25 2022-07-01 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
BR112022014212B1 (pt) 2020-01-21 2024-01-23 Regeneron Pharmaceuticals, Inc Métodos de análise de uma amostra incluindo uma proteína de interesse
EP4204449A1 (en) 2020-08-26 2023-07-05 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
CA3213283A1 (en) 2021-03-11 2022-09-15 IgGenix, Inc. Methods and systems for predicting allergic response
US20220309215A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CN118139881A (zh) 2021-09-20 2024-06-04 瑞泽恩制药公司 控制抗体异质性的方法
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
CN114113278B (zh) * 2021-11-24 2024-08-02 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
CA3251374A1 (en) 2022-06-23 2023-12-28 Regeneron Pharmaceuticals, Inc. METHODS FOR IDENTIFYING AND EVALUATING GENETIC SIGNATURES OF CAT ALLERGY IN A SUBJECT BY DETERMINING A STRATIFIED SCORE BASED ON GENE EXPRESSION.
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024158880A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
IL322811A (en) 2023-03-01 2025-10-01 Regeneron Pharma Anti-FEL D1 antibody formulations
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用
TW202528736A (zh) 2023-09-08 2025-07-16 美商再生元醫藥公司 用於評估層析管柱完整性的方法及系統
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
CN117069865B (zh) * 2023-10-12 2024-03-01 中国农业科学院饲料研究所 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN117964767B (zh) * 2024-03-29 2024-08-06 北京恩泽康泰生物科技有限公司 抗rage抗体、细胞外囊泡及其制备方法和应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
WO1993013772A1 (en) 1992-01-21 1993-07-22 Immulogic Pharmaceutical Corporation Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
EP0675734A4 (en) 1992-12-21 1997-05-07 Tanox Biosystems Inc MONOCLONAL ALLERGEN-SPECIFIC IgA ANTIBODIES AND RELATED PRODUCTS FOR THE TREATMENT OF ALLERGIES.
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
NZ561040A (en) * 2005-03-18 2009-04-30 Cytos Biotechnology Ag Cat allergen fusion proteins and use thereof
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
GB0513878D0 (en) * 2005-07-06 2005-08-10 Mars Inc Cat allergen
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
WO2007113633A2 (en) * 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1921142A1 (en) * 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2008234248C1 (en) * 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
CA2688275A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
HUE034431T2 (en) * 2007-07-09 2018-02-28 Nestec Sa Procedures to reduce allergies caused by environmental allergens
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AU2011312191B2 (en) 2010-10-06 2015-07-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2018118713A1 (en) 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies

Also Published As

Publication number Publication date
US20160376358A1 (en) 2016-12-29
ZA202005273B (en) 2023-11-29
CN110240651A (zh) 2019-09-17
JP2017153491A (ja) 2017-09-07
EP3660047A1 (en) 2020-06-03
NZ733480A (en) 2019-03-29
EP2844672A1 (en) 2015-03-11
NZ701124A (en) 2017-07-28
US20130295097A1 (en) 2013-11-07
PT2844672T (pt) 2020-04-30
US10047153B2 (en) 2018-08-14
CY1124819T1 (el) 2022-11-25
FI3978522T3 (fi) 2025-11-13
EP3978522B1 (en) 2025-10-01
US9475869B2 (en) 2016-10-25
RU2014148502A (ru) 2016-06-27
MY195564A (en) 2023-02-02
EP3978522A2 (en) 2022-04-06
HRP20211932T1 (hr) 2022-03-18
JP2015523962A (ja) 2015-08-20
US11174305B2 (en) 2021-11-16
BR112014026852A2 (pt) 2017-07-18
SI2844672T1 (sl) 2020-07-31
JO3820B1 (ar) 2021-01-31
US9079948B2 (en) 2015-07-14
AR090914A1 (es) 2014-12-17
SG10201608378UA (en) 2016-11-29
PL3660047T3 (pl) 2022-02-14
LT3660047T (lt) 2021-11-10
CN104411719A (zh) 2015-03-11
SMT202000241T1 (it) 2020-07-08
AU2018203087B9 (en) 2020-03-26
ES2780392T3 (es) 2020-08-25
IN2014DN08767A (es) 2015-05-22
ES3049982T3 (en) 2025-12-19
EP4653056A2 (en) 2025-11-26
US12252530B2 (en) 2025-03-18
EP2844672B1 (en) 2020-02-12
EP3660047B1 (en) 2021-10-13
HUE049440T2 (hu) 2020-09-28
DK3978522T3 (da) 2025-10-27
SI3978522T1 (sl) 2025-11-28
CN110240651B (zh) 2024-03-08
PL2844672T3 (pl) 2020-08-10
HK1202123A1 (en) 2015-09-18
AU2013256251B2 (en) 2018-04-12
US20150299303A1 (en) 2015-10-22
LT3978522T (lt) 2025-11-25
ZA201407302B (en) 2021-08-25
SI3660047T1 (sl) 2021-12-31
SMT202500396T1 (it) 2025-11-10
AU2013256251A1 (en) 2014-11-06
MY181422A (en) 2020-12-21
US20180305446A1 (en) 2018-10-25
CN104411719B (zh) 2019-05-14
US10047152B2 (en) 2018-08-14
JP6603269B2 (ja) 2019-11-06
WO2013166236A1 (en) 2013-11-07
US20220025029A1 (en) 2022-01-27
PT3978522T (pt) 2025-10-17
PT3660047T (pt) 2021-11-30
EP3978522A3 (en) 2022-07-06
DK2844672T3 (da) 2020-04-20
HRP20200652T1 (hr) 2020-07-10
CY1124023T1 (el) 2022-03-24
CA2871077C (en) 2021-08-17
AU2018203087B2 (en) 2020-03-12
IL235121A0 (en) 2014-12-31
SG11201406748QA (en) 2014-11-27
KR102185516B1 (ko) 2020-12-02
TW201406779A (zh) 2014-02-16
BR122019023685B1 (pt) 2023-01-17
KR20150005666A (ko) 2015-01-14
CA2871077A1 (en) 2013-11-07
SMT202200014T1 (it) 2022-03-21
ZA202202846B (en) 2023-11-29
RS62636B1 (sr) 2021-12-31
MX2014013371A (es) 2015-02-05
MY164101A (en) 2017-11-30
RS60282B1 (sr) 2020-06-30
IL235121B (en) 2019-06-30
LT2844672T (lt) 2020-04-10
ES2898372T3 (es) 2022-03-07
MX2020003864A (es) 2020-08-13
TW201803901A (zh) 2018-02-01
RU2658491C2 (ru) 2018-06-21
AU2018203087A1 (en) 2018-05-24
SG10202102919XA (en) 2021-05-28
TWI644921B (zh) 2018-12-21
UY34782A (es) 2013-11-29
HUE057062T2 (hu) 2022-04-28
AU2013256251C1 (en) 2018-08-23
BR112014026852B1 (pt) 2023-01-03
US20170210790A1 (en) 2017-07-27
JP6400569B2 (ja) 2018-10-03

Similar Documents

Publication Publication Date Title
ZA202202846B (en) Human antibodies to fel d1 and methods of use thereof
PH12019550238A1 (en) Human antibodies to bet v 1 and methods of use thereof
IL285475A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
PH12013500564A1 (en) Anti-cd48 antibodies and uses thereof
MY146664A (en) Antibodies against human il-22 and uses therefor
EP2558478A4 (en) AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE
MY171180A (en) Anti-hla-b*27 antibodies and uses thereof
EA201590247A1 (ru) Антитела к siglec-15
MX345730B (es) Células adherentes derivadas del amnios (amdac) para usarse en el tratamiento de enfermedades y trastornos relacionados con el sistema inmunitario.
PH12012500843A1 (en) Engineered anti-tslp antibody
WO2013173761A3 (en) St2 antigen binding proteins
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Wei-Jie Interpretation of Culture——Luria’s View of Cultural Psychology and Contemporary Psychological Development
UA108088C2 (xx) Сконструйоване антитіло проти tslp
UA113833C2 (xx) Зв'язуючі il-1 білки
HK1190415A (en) Humanised anti-cd52 antibodies

Legal Events

Date Code Title Description
FG Grant or registration